Background
==========

Invasive fungal infections caused by *Candida*species have increased significantly. They now rank fourth as the most common cause of nosocomial bloodstream infections in the United Stated \[[@B1]\] and the most common one at one major hospital in Taiwan \[[@B2]\]. Candidemia is not only associated with a mortality of about 30% to 40% but also extends the duration of hospital stay \[[@B3],[@B4]\] and increases the cost for medical care \[[@B5]\]. In recent years, *Candida*species associated with candidemia have shifted from *Candida albicans*to non-albicans *Candida*species (NAC) \[[@B6]\]. Approximately half of the reported cases of candidemia are now caused by NAC \[[@B7]-[@B10]\].

Patients with candidemia usually present an acute septic syndrome that is indistinguishable from bacteremia, but they may also exhibit a more indolent course manifested by fever of unknown origin. Major risk factors for candidemia include intravascular catheters, parenteral hyperalimentation, and broad-spectrum antibiotics. Empirical antifungal agents may be administrated to patients manifested with fever of unknown origin and have above mentioned risk factors, particularly those who have been treated with broad-spectrum antibiotics. The clinical presentation of the patients with sepsis caused by *C. albicans*and NAC are indistinguishable. However, NAC are often less susceptible to fluconazole than *C. albicans*is \[[@B7],[@B11],[@B12]\] and may require greater dosage to cure clinically \[[@B13],[@B14]\].

We have conducted a retrospective chart review of patients whose death was associated with candidemia. The goal was to assist decisions to select the most appropriate empirical therapy for patients suspected to have candidemia. The objective was to determine whether specific risk factors could be identified to help selecting those patients who are more likely infected with *C. albicans*versus NAC.

Methods
=======

This study was conducted at the Veterans General Hospital-Taipei. This is a 2800-bed teaching hospital with about 69,000 admissions annually \[[@B7]\]. A total of 415 blood isolates of *Candida*species (one strain per species per patient) were collected from April 1996 to December 1999. During this period 130 patients met the inclusion criteria of having at least one positive blood culture for *Candida*species within one month prior to the fatal outcome. There were 68 patients infected with *C. albicans*and 62 with NAC.

*Candida*species were isolated from blood using BACTEC 860 system (Becton Dickinson, INC, Sparks, MD). The species were identified using API-32C system (bioMerieux Vitek, Inc, St. Louis, MI).

Clinical data
-------------

Clinical data of 130 patients were recorded on standardized forms and analyzed according to age at the time of diagnosis, gender and underlying illnesses. These included cancer, diabetes, immunosuppression accounted to prior use of steroids, systemic antifungal agents, cancer chemotherapy, parenteral nutrition, the presence of central or arterial line, endotracheal tube, and urinary catheter, admission to an intensive care unit (ICU), history of infection or gastrointestinal surgery, hemogram, antifungal management, and cause of death. The predisposing events within one month prior to diagnosis and the laboratory data within seven days prior to obtaining the first positive blood culture were analyzed. To decide that a patient died directly of candidemia or underlying illness, we recoded the causes of death according to the death certificate of the patients.

Statistical analysis
--------------------

The statistical significance of association between categorical variables was assessed using the Fisher\'s Exact Test. The risk factors with p values \< 0.1 in the univariate analysis were placed in a multivariate analysis using the multiple logistic regression package in the SAS System for Windows V8. Confidence limit of 95% means that the confidence limit contains the true value of odds ratio with probability of 0.95. The narrower the confidence limit is, the more accurate the estimate is.

Results
=======

The population consisted of 130 patients whose death was associated with candidemia. Fifty-five (42.3 %) of these deaths were considered to be directly caused by *Candida*species. The remaining died of complications of their underlying illness. The distribution of species of the total deaths and those causally related to candidemia is shown in Table [1](#T1){ref-type="table"}. There were no significant differences in causation of death according to species. Interestingly, of the four major species related to candidemia, 61.5% of the isolated *Candida glabrata*contributed to mortality, followed by 50% of *Candida parapsilosis*, 41.2% of *C. albicans*, and 31.3% of *Candida tropicalis*.

###### 

Distribution of *Candida species*of fatal outcome attributed to disseminated candidemia

                                  Blood isolates (N = 130)   Death directly related to candidemia (N = 55)               
  ------------------------------- -------------------------- ----------------------------------------------- ---- ------ -------
  *C. albicans*                   68                         52.3                                            28   50.9   41.2
  non-albicans *Candida*species   62                         47.7                                            27   49.1   43.5
   *C. tropicalis*                32                         24.7                                            10   18.2   31.3
   *C. glabrata*                  13                         10.0                                            8    14.5   61.5
   *C. parapsilosis*              12                         9.2                                             6    10.9   50.0
   *C. guilliermondii*            2                          1.5                                             1    1.8    50.0
   *C. peniculosa*                2                          1.5                                             2    3.6    100.0
   *C. famata*                    1                          0.8                                             0    0      0

The demographic and clinical characteristics of the study population categorized according to the presence of *C. albicans*or NAC in the blood are summarized in Table [2](#T2){ref-type="table"}. The significant (*p*≤ 0.05) risk factors on univariate analysis for *C. albicans*candidemia were age ≧ 65 years, prior bacterial urinary tract infection, central venous catheter, parenteral nutrition and leucocytosis with white blood cell counts (WBC) ≧ 15000/mm^3^, without significant neutropenia with absolute neutrophil counts (ANC) ≧ 100000/mm^3^. The significant risk factors for NAC were age \< 65 years, cancer chemotherapy, neutropenia (WBC \< 3000/mm^3^) and severe thrombocytopenia (platelet count ≦ 20000 /mm^3^). NAC patients were more likely to have cancers and to be located on the medical wards (p = 0.08). When multivariate analysis was employed, the significant risk factors for *C. albicans*were age ≧ 65 years, immunosuppressive therapy, and leucocytosis. Significant risk factors for NAC were age \< 65 years and location on medical wards, which are shown in Table [3](#T3){ref-type="table"}.

###### 

Characteristics of 130 patients who died in association with candidemia

  ----------------------------------- ----------------------- -------------- ---------------------- ------ -------------------
  Characteristic                      *C. albicans*(N = 68)   NAC (N = 62)   Fisher\'s Exact Test          
                                      No.                     \%             No.                    \%     Two-sided P-value
                                                                                                           
  Age ≧ 65 years old                  56                      82.4           36                     58.1   **0.004\***
  MICU                                6                       8.8            10                     16.1   0.286
  Medical ward stay                   24                      35.3           32                     51.6   0.077\*
  Cancer                              24                      35.3           32                     51.6   0.077\*
  Immunosuppressive therapy           17                      25             7                      11.3   0.069\*
  Bacteremia                          25                      36.8           15                     24.2   0.133
  Bacterial urinary tract infection   23                      33.8           10                     16.1   **0.026\***
  Prior antifungal administration     5                       7.4            9                      14.5   0.259
  Catheters within 30 days            65                      95.6           56                     90.3   0.309
    ETT                               35                      51.5           23                     37.1   0.114
    CVC                               57                      83.8           41                     66.1   **0.025\***
    AL                                21                      30.9           14                     22.6   0.326
    Urinary catheter                  49                      72.1           39                     62.9   0.348
  PPN                                 50                      73.5           34                     54.8   **0.029\***
  Cancer chemotherapy                 5                       7.4            12                     19.4   0.066\*
  Corticosteroids                     26                      38.2           18                     29     0.354
  ANC                                 (N = 44)                (N = 40)       1                             
    ANC ≦ 1500/mm^3^                  2                       4.5            2                      5      
  WBC                                 (N = 67)                (N = 61)       **0.0004\***                  
    ≦ 3000/mm^3^                      4                       6              14                     23     
    3000/mm^3^to 5000/mm3             35                      52.2           38                     62.3   
    \> 15000/mm^3^                    28                      41.8           9                      14.8   
  Platelet                            (N = 66)                (N = 61)       **0.011\***                   
    ≦ 20000/mm^3^                     5                       7.6            10                     16.4   
    20000/mm^3^to 100000/mm^3^        20                      30.3           29                     47.5   
    \> 100000/mm^3^                   41                      62.1           22                     36.1   
  ----------------------------------- ----------------------- -------------- ---------------------- ------ -------------------

\* Factors selected for multivariate analysis. AL, arterial line; ANC, absolute neutrophil count; CVC, central venous catheter; ETT, endo trachial tube; ICU, Intensive care unit; PN, parenteral nutrition; WBC, white blood cell

###### 

Multiple regression analysis of risk factors for candidemia caused by *Candida albicans*vs. non-albicans Candida species

  ----------------------------------------- ------------ ----------------------- --------- --------
  Effect                                    Odds Ratio   95% confidence Limits   P-value   
                                                                                           
  White Blood Cell (WBC)                                                                   0.0202
    \> 15000/mm^3^vs. ≦ 3000/ mm^3^         5.89         1.35                    25.7      0.0184
    3001 -- 15000/mm^3^vs. ≦ 3000/ mm^3^    1.66         0.44                    6.26      0.4549
    \> 15000/mm^3^vs. 3001 -- 15000/mm^3^   3.55         1.29                    9.79      0.0144
  Age65 (≧ 65 vs. \< 65)                    6.73         2.37                    19.1      0.0003
  Immunosuppressive therapy                 4.39         1.26                    15.32     0.0201
  Located on a medical ward                 0.37         0.16                    0.88      0.025
  ----------------------------------------- ------------ ----------------------- --------- --------

Discussion
==========

*Candida albicans*remains the most common species causing candidemia, but the proportion caused by NAC is increasing \[[@B7]-[@B10]\]. Patients with NAC are more likely to require greater dosage of fluconazole to cure clinically \[[@B13],[@B14]\]. Thus there is a need to identify patients at risk of NAC candidemia to initiate empirical amphotericin B therapy or high-dose fluconazole.

Krcmery and Barnes have identified the following risk factors for NAC \[[@B15]\]. These include prophylaxis with azole compounds as a risk factor for *C. krusei*and *C. glabrata*, neutropenia and bone marrow transplantation for *C. tropicalis*, and insertion of foreign bodies, neonates, and hyperalimentation for *C. parapsilosis*\[[@B15]-[@B18]\]. In this study we have identified additional risk factors that help distinguish candidemia caused by *C. albicans*and NAC. The most important risk factors for *C. albicans*are the old age, procedures associated with intensive care, and an acute sepsis. The most important risk factors for NAC are cancer chemotherapy in association with leukopenia and thrombocytopenia.

It has been reported that *Candida*species exhibit a spectrum in the extent of adherence to tissues, which correlates with the pathogenicity in humans and animals \[[@B19]\]. *Candida albicans*exhibit the greatest capacity to adhere to gingival epithelial cells, followed by *C. tropicalis*and *C. glabrata*\[[@B19]\]. The capacity of yeasts to attach to a wide range inanimate surfaces appears to protect them from immune responses and antimicrobial agents \[[@B20]\]. This may explain why *C. albicans*is more likely to be associated with central venous catheters in this study.

Conventional methods to eradicate *C. albicans*rely upon the use of antifungal drugs designed to kill the yeast or arrest its growth. However, removal of intravascular catheters is in fact the most simple and effective method \[[@B21],[@B22]\]. Another approach is to design new agents that disrupt adherence of the yeasts to host tissues and catheters.

Conclusion
==========

It is customary to administer amphotericin B for critically ill patients suspected of having candidemia. More often than not, azoles are used for relatively stable patients. NAC tend to be less susceptible to fluconazole than *C. albicans*is \[[@B7],[@B11],[@B23]\]. Thus, greater dosage is needed till the causative microorganism is isolated and identified, particularly with patients at high risk for NAC candidemia. Though, a large, prospective study is needed to validate this concept, the risk factors identified in this study may help, in clinical practice, to differentiate fatal candidemia caused by *C. albicans*versus NAC.
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